Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4894MR)

This product GTTS-WQ4894MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4894MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7550MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ4951MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ7436MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ3627MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ7541MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ10024MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ959MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ1990MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW